NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?

Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Smolenschi, Cristina, Colomba, Emeline, Rassy, Elie, Lezghed, Naima, Kettab, Mohamed, Louvel, Guillaume, Garcia, Gabriel, Cheaib, Bianca, Bockel, Sophie, Pallud, Johan, Dezamis, Edouard, Copaciu, Razvan, Knafo, Steven, Ammari, Samy, Dhermain, Frederic, Domont, Julien, Martanovschi, Larisa, Mahmoud, Fekih, Dumont, Sarah
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Outcome Measures and Neuro-Cognitive Outcomes
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651623/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.558
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares